Wallington Asset Management LLC trimmed its position in Amgen, Inc. (NASDAQ:AMGN) by 0.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,314 shares of the medical research company’s stock after selling 530 shares during the quarter. Amgen makes up approximately 3.2% of Wallington Asset Management LLC’s holdings, making the stock its 8th largest position. Wallington Asset Management LLC’s holdings in Amgen were worth $12,402,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Bruderman Asset Management LLC boosted its position in Amgen by 21.4% during the 4th quarter. Bruderman Asset Management LLC now owns 15,545 shares of the medical research company’s stock valued at $2,703,000 after purchasing an additional 2,740 shares during the period. Northwest Capital Management Inc acquired a new position in Amgen during the 4th quarter valued at approximately $334,000. BT Investment Management Ltd boosted its position in Amgen by 5.9% during the 4th quarter. BT Investment Management Ltd now owns 88,849 shares of the medical research company’s stock valued at $15,451,000 after purchasing an additional 4,962 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Amgen by 1.0% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,095,237 shares of the medical research company’s stock valued at $364,362,000 after purchasing an additional 20,969 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Amgen by 1.0% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 111,254 shares of the medical research company’s stock valued at $20,064,000 after purchasing an additional 1,151 shares during the period. Institutional investors and hedge funds own 79.50% of the company’s stock.
In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 4,575 shares of company stock worth $838,064 in the last three months. Company insiders own 0.19% of the company’s stock.
Amgen, Inc. (NASDAQ AMGN) opened at $176.08 on Friday. Amgen, Inc. has a 12-month low of $152.16 and a 12-month high of $201.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The stock has a market capitalization of $130,846.88, a price-to-earnings ratio of 14.44, a price-to-earnings-growth ratio of 2.23 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. During the same period in the prior year, the firm posted $2.89 EPS. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. sell-side analysts expect that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.
Amgen announced that its board has approved a share buyback program on Thursday, February 1st that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio is presently 205.45%.
A number of research firms recently issued reports on AMGN. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $181.60 price objective for the company. in a research report on Tuesday, March 6th. Mizuho boosted their price objective on Amgen from $192.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, February 12th. Atlantic Securities lowered Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price objective for the company. in a research report on Monday, February 5th. JPMorgan Chase & Co. restated a “hold” rating and set a $191.00 price objective on shares of Amgen in a research report on Sunday, February 4th. Finally, Leerink Swann restated a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company. Amgen presently has an average rating of “Hold” and an average price target of $191.26.
TRADEMARK VIOLATION NOTICE: “Amgen, Inc. (AMGN) Shares Sold by Wallington Asset Management LLC” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2018/03/23/amgen-inc-amgn-shares-sold-by-wallington-asset-management-llc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.